Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY2666605 |
Synonyms | |
Therapy Description |
BAY2666605 induces formation of the SLFN12-PDE3A complex, leading to stimulation of SLFN12 activity and decreased inhibition of PDE3A enzymatic activity, potentially reducing cancer cell viability and inhibiting tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2663). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY2666605 | BAY 2666605|BAY-2666605|Doxorubicin-loaded EGFR-targeting Nanocells | BAY2666605 induces formation of the SLFN12-PDE3A complex, leading to stimulation of SLFN12 activity and decreased inhibition of PDE3A enzymatic activity, potentially reducing cancer cell viability and inhibiting tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2663). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04809805 | Phase I | BAY2666605 | A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer | Terminated | USA | 0 |